<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Linwah Yip, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shonni J Silverberg, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ghada El-Hajj Fuleihan, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sally E Carty, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford J Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary hyperparathyroidism is usually caused by a solitary benign adenoma (80 to 85 percent) but can also be due to double adenomata (2 to 5 percent), diffuse or nodular hyperplasia (10 to 15 percent), or parathyroid carcinoma (&lt;1 percent) [
         <a href="#rid1">
          1
         </a>
         ]. An open four-gland parathyroid exploration has traditionally been considered the gold standard for patients undergoing surgery for primary hyperparathyroidism. However, a more focused, minimally invasive approach to parathyroid surgery has been adopted at many centers [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         Localization techniques are primarily used in patients who have biochemically confirmed sporadic primary hyperparathyroidism to identify patients who are candidates for a minimally invasive approach. They are also important in patients who have persistent or recurrent disease, or who have had prior cervical exploration and require remedial surgery. Patients with hereditary primary hyperparathyroidism generally undergo bilateral parathyroid exploration, even in the event of a positive localizing study, because of the high likelihood of multiglandular disease. Localization studies, in conjunction with intraoperative parathyroid hormone testing, can help minimize the extent of surgical dissection, identify concurrent thyroid pathology, and detect ectopic parathyroid tissue, the latter being a particular advantage for patients who had prior failed parathyroid exploration. However, localization studies should not be used to diagnose or confirm the diagnosis of primary hyperparathyroidism or determine the need for surgery. Use of localization studies does not override the recommendation that parathyroid surgery should only be performed by highly experienced surgeons [
         <a href="#rid2">
          2,4
         </a>
         ].
        </p>
        <p>
         The techniques and role of preoperative localization in patients with primary hyperparathyroidism will be reviewed here. Decision making regarding the role of surgical therapy, the details of surgical management in these patients, and the role of surgery for secondary hyperparathyroidism in patients with end-stage kidney disease are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">
          "Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">
          "Parathyroid exploration for primary hyperparathyroidism", section on 'Focused parathyroid exploration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">
          "Primary hyperparathyroidism: Management", section on 'Candidates for surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H238328935">
         <span class="h1">
          ROLE OF PREOPERATIVE LOCALIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of primary hyperparathyroidism should be made based upon biochemical findings. Imaging studies are not used as a diagnostic tool, because of high false-positive rates, which can range from 5 to 25 percent  (
         <a class="graphic graphic_table graphicRef88628" href="/z/d/graphic/88628.html" rel="external">
          table 1
         </a>
         ). In addition, a single-focus positive imaging result does not reliably exclude the presence of multiglandular parathyroid disease [
         <a href="#rid5">
          5
         </a>
         ]. Rather, preoperative localization studies help plan the operative approach in patients who have a biochemically confirmed diagnosis of primary hyperparathyroidism, and in whom other pathologies have been appropriately ruled out (eg, familial hypocalciuric hypercalcemia). For patients undergoing initial surgery, these studies are predominantly used to determine whether or not a patient is a candidate for a minimally invasive approach [
         <a href="#rid6">
          6-8
         </a>
         ]. Parathyroid localization techniques are generally less successful in normocalcemic primary hyperparathyroidism than in hypercalcemic disease [
         <a href="#rid9">
          9
         </a>
         ]. This may be due to a greater incidence of multiglandular disease and smaller adenoma size in normocalcemic patients. (See
         <a class="medical medical_review" href="/z/d/html/2055.html" rel="external">
          "Parathyroid hormone assays and their clinical use"
         </a>
         .)
        </p>
        <p>
         Available radiologic expertise is an important factor in choosing the type of localization testing to be performed. Localization images should be displayed and available intraoperatively since review during exploration often usefully guides successful surgery. (See
         <a class="local">
          'Imaging modalities'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H238328983">
         <span class="h2">
          Minimally invasive and unilateral parathyroidectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative localization reduces operative time in unilateral parathyroid surgery and is required if a minimally invasive procedure is contemplated [
         <a href="#rid10">
          10-12
         </a>
         ]. The success of a minimally invasive approach is dependent upon accurate imaging results, which aid in limiting the dissection to the region where the adenoma has been localized. For every parathyroid operation, the goal is cure of the biochemical condition, and, thus, intraoperative parathyroid hormone (PTH) assay should be used to confirm success of the operation by demonstrating a substantial drop in parathyroid hormone level [
         <a href="#rid13">
          13-15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">
          "Parathyroid exploration for primary hyperparathyroidism", section on 'Intraoperative assessment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15031.html" rel="external">
          "Intraoperative parathyroid hormone assays"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H238329064">
         <span class="h2">
          Reoperation for recurrent or persistent hyperparathyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two to 10 percent of patients undergoing surgery for hyperparathyroidism have recurrent or persistent disease, and the likelihood of failed surgery is dependent on the length of postoperative follow-up and surgeon volume [
         <a href="#rid16">
          16,17
         </a>
         ]. In such cases, the diagnosis of primary hyperparathyroidism should be confirmed biochemically, and indications for surgery should be reevaluated. Accurate localization studies are mandatory in patients undergoing reoperative surgery. Because of fibrosis from the previous surgery and alterations in parathyroid gland location, the rate of complications, such as recurrent laryngeal nerve injury, permanent hypoparathyroidism, and persistent disease, is typically higher [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         At least one preoperative imaging study should localize hyperfunctional parathyroid tissue before proceeding with re-exploration and may include sestamibi scan, sestamibi with single-photon emission computed tomography (SPECT), ultrasound, and/or four-dimensional computed tomography (4D-CT) [
         <a href="#rid2">
          2,20,21
         </a>
         ]. The success rate of reoperative surgery without preoperative localization is only 60 percent. Several observational studies have reported success rates of 95 percent or more with positive preoperative localization before reoperation [
         <a href="#rid18">
          18,22,23
         </a>
         ]. Almost 30 percent of patients undergoing reoperation have multiple gland disease. Thus, localization studies identifying an apparent single adenoma do not exclude the existence of abnormal parathyroid glands in other locations.
        </p>
        <p>
         The best imaging study or combination of studies for persistent disease has not been determined. In most reports assessing different imaging modalities, SPECT/CT often is the first imaging study utilized in the reoperative setting and can detect 60 to 80 percent of the abnormal glands [
         <a href="#rid24">
          24,25
         </a>
         ]. A study of 90 patients who required reoperative surgery reported high postoperative cure rates but shorter operative times when 4D-CT was used for preoperative localization [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Ultrasound- or CT-guided fine needle aspiration of suspicious lesions for PTH assay can be performed to confirm that the lesion is parathyroid tissue [
         <a href="#rid27">
          27,28
         </a>
         ]. In a study of 44 patients, fine needle aspiration with PTH assay had a specificity and sensitivity of 100 and 70 percent, respectively [
         <a href="#rid28">
          28
         </a>
         ]. Fine needle aspiration should not be performed if the diagnosis of parathyroid cancer is considered likely, as seeding of the cancer is a potential complication [
         <a href="#rid2">
          2
         </a>
         ]. Selective arterial or venous angiography is usually the next localization modality used if multiple noninvasive imaging techniques fail to identify an abnormality [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p>
         Algorithms for the evaluation of patients undergoing reoperation have been developed  (
         <a class="graphic graphic_figure graphicRef78548" href="/z/d/graphic/78548.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid32">
          32,33
         </a>
         ]. These algorithms, which are based upon clinical experience, suggest performing two noninvasive procedures prior to reoperation, one of which should be sestamibi imaging. The other is often ultrasonography, but choice is dictated by available expertise. If the results of these studies are concordant, surgery is performed. If the results are discordant or inconclusive, the next step depends upon the expertise of the referral center and may include either surgery with intraoperative monitoring of PTH or additional testing [
         <a href="#rid32">
          32,33
         </a>
         ]. Further testing includes additional imaging (CT, MRI) or possible invasive procedures (selective venous sampling). Several observational studies showed that this approach allowed the identification of the offending parathyroid gland or glands in 92 to 97 percent of reoperated cases [
         <a href="#rid23">
          23,32,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H238329446">
         <span class="h2">
          Bilateral neck exploration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilateral parathyroid exploration should be planned when imaging studies are negative or show more than one focus of activity, in cases of secondary or tertiary hyperparathyroidism, suspected hereditary etiology, or when concurrent thyroid pathology is present and warrants surgery. Bilateral exploration should also be considered for male patients under the age of 30 years because of the increased incidence of multiple endocrine neoplasia in these patients [
         <a href="#rid34">
          34
         </a>
         ]. In the hands of experienced surgeons, bilateral exploration has a high cure rate and low morbidity [
         <a href="#rid35">
          35-39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">
          "Parathyroid exploration for primary hyperparathyroidism", section on 'Bilateral parathyroid exploration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          IMAGING MODALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As mentioned above, imaging studies are obtained only after biochemical confirmation of primary hyperparathyroidism and are used predominantly to help plan the operative approach [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="local">
          'Role of preoperative localization'
         </a>
         above.)
        </p>
        <p>
         Sestamibi scintigraphy (technetium-99-sestamibi scanning) combined with sestamibi single photon emission computed tomography (SPECT) has the highest positive predictive value of the available imaging techniques, and some prefer this as the localizing procedure of choice for initial surgery [
         <a href="#rid3">
          3,41,42
         </a>
         ]. However, SPECT is not available at all centers, and some use planar sestamibi as the initial localizing study. Additional complementary techniques are needed for patients with persistent/recurrent disease or inconclusive results on sestamibi or SPECT scanning. Imaging modalities that have also been used successfully include ultrasound, SPECT combined with computed tomography (MIBI-SPECT-CT fusion), four-dimensional computed tomography (4D-CT), and 11C-methionine positron emission tomography (PET) combined with CT [
         <a href="#rid29">
          29,41,43-48
         </a>
         ]. The utility of these tests is discussed in the following sections. The sensitivity and positive predictive value of the imaging modalities are summarized in the table  (
         <a class="graphic graphic_table graphicRef88628" href="/z/d/graphic/88628.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2890373">
         <span class="h2">
          Sestamibi scintigraphy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Technetium-99m-methoxyisobutylisonitrile (99mTc-sestamibi or MIBI) was first used for cardiac scintigraphy and was noted to concentrate in parathyroid adenomas. 99mTc-sestamibi is taken up by the mitochondria in thyroid and parathyroid tissue; however, the radiotracer is retained by the mitochondria-rich oxyphil cells in parathyroid glands longer than in thyroid tissue [
         <a href="#rid49">
          49
         </a>
         ]. Planar images are typically obtained shortly after injection of 99mTc-sestamibi and again at approximately two hours to identify foci of retained radiotracer activity consistent with hyperfunctioning parathyroid tissue. Sestamibi scintigraphy alone provides limited anatomic detail.
        </p>
        <p>
         A negative 99mTc sestamibi scan does not negate the diagnosis of primary hyperparathyroidism, since it occurs in 12 to 25 percent of patients with disease [
         <a href="#rid50">
          50,51
         </a>
         ]. Sestamibi scanning is often unrevealing, or misleading, in patients with parathyroid hyperplasia, multiple parathyroid adenomas, and coexisting thyroid disease [
         <a href="#rid10">
          10,52-58
         </a>
         ]. Thyroid disease requiring surgery significantly increases both the false positive and false negative rate of sestamibi scanning [
         <a href="#rid59">
          59
         </a>
         ]. Falsely negative scans can also be caused by calcium channel blockers that interfere with the uptake of the isotope by parathyroid cells [
         <a href="#rid56">
          56
         </a>
         ]. Other gland characteristics that can increase the likelihood of a negative scan include small size, superior position, and a paucity of oxyphil cells [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
         Sestamibi scanning for parathyroid tissue can be enhanced by combination with three-dimensional imaging (SPECT), a subtraction thyroid scan, or fusion with computed tomography images (MIBI-SPECT-CT) [
         <a href="#rid52">
          52,60,61
         </a>
         ]. These are discussed below.
        </p>
        <p class="headingAnchor" id="H257607">
         <span class="h3">
          SPECT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sestamibi-single photon emission computed tomography (SPECT or MIBI-SPECT) is a three-dimensional sestamibi scan that provides higher-resolution imaging and improves the performance of sestamibi scanning  (
         <a class="graphic graphic_diagnosticimage graphicRef50315" href="/z/d/graphic/50315.html" rel="external">
          image 1
         </a>
         ). The multidimensional images illustrate the depth of the parathyroid gland or glands in relation to the thyroid and improve detection of ectopic glands, which facilitates minimally invasive parathyroidectomy [
         <a href="#rid55">
          55,60,62,63
         </a>
         ].
        </p>
        <p>
         In single-institution comparison studies utilizing a variety of imaging protocols, the addition of SPECT improves the sensitivity for identifying abnormal parathyroid glands to 92 to 98 percent as compared with 71 to 79 percent for planar sestamibi scintigraphy [
         <a href="#rid52">
          52,55,60,62,63
         </a>
         ]. As an example, in a prospective study of 338 patients with primary hyperparathyroidism, SPECT imaging successfully detected 96 percent of solitary adenomas and 83 percent of double adenomas [
         <a href="#rid52">
          52
         </a>
         ]. However, only 45 percent of multiglandular hyperplasias were detected.
        </p>
        <p>
         SPECT imaging substantially reduces the likelihood of missing multiglandular disease compared with planar imaging [
         <a href="#rid5">
          5,64
         </a>
         ]. However, even with imaging showing a clear, bright focus of increased uptake, multiglandular disease is still a possibility [
         <a href="#rid5">
          5,50,52,64
         </a>
         ]. Because SPECT imaging has a high rate (7 to 16 percent) [
         <a href="#rid5">
          5,65,66
         </a>
         ] of missed multiglandular disease, a validated adjunct to exclude multiglandular disease such as intraoperative parathyroid hormone monitoring or four-gland parathyroid exploration should be routinely utilized.
        </p>
        <p class="headingAnchor" id="H257614">
         <span class="h3">
          SPECT and CT fusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         SPECT-CT adds the ability to discriminate parathyroid adenomas from other anatomic landmarks, which may facilitate the surgical procedure [
         <a href="#rid43">
          43,61,64,67
         </a>
         ]. In a single-institution retrospective and observational study of 1388 patients who underwent parathyroid exploration for primary hyperparathyroidism, SPECT-CT had greater accuracy for both single-gland disease (83 versus 77 percent) and multigland disease (36 versus 22 percent) than SPECT alone. The negative imaging rates were similar between the two imaging cohorts (about 10 percent) [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6957677">
         <span class="h3">
          Subtraction thyroid scan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even with the addition of SPECT, distinguishing abnormal parathyroid glands from thyroid pathology can be difficult. If necessary, a subtraction thyroid scan can be obtained by using two radiotracers (dual isotope scintigraphy). The use of technetium plus a second radiotracer such as 123I or 99mTc pertechnetate (thallium) permits selective imaging of the thyroid gland.
        </p>
        <p class="headingAnchor" id="H1267381">
         <span class="h2">
          Ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neck ultrasonography (US) is also often utilized for parathyroid localization  (
         <a class="graphic graphic_diagnosticimage graphicRef71417" href="/z/d/graphic/71417.html" rel="external">
          image 2
         </a>
         ). Sonographic characteristics of parathyroid adenomas include homogeneous hypoechogenicity and an extrathyroidal feeding vessel with peripheral vascularity seen on color Doppler imaging  (
         <a class="graphic graphic_diagnosticimage graphicRef62112" href="/z/d/graphic/62112.html" rel="external">
          image 3
         </a>
         ).
        </p>
        <p>
         US is highly sensitive in experienced hands and is inexpensive, noninvasive, and reproducible in the operating room. In reoperative cases, intraoperative US can be used to localize the adenoma and facilitate surgery in a previously dissected and scarred field. However, the accuracy of ultrasound is operator dependent as the sensitivity of ultrasound for detecting enlarged parathyroid glands ranges from 72 to 89 percent [
         <a href="#rid47">
          47,69-71
         </a>
         ]. It is advantageous for experienced endocrine surgeons to learn to perform neck ultrasound [
         <a href="#rid65">
          65
         </a>
         ], and studies have shown comparable sensitivity for localizing parathyroid adenomas compared to radiologist-performed ultrasound (77 to 87 percent) [
         <a href="#rid65">
          65,72
         </a>
         ].
        </p>
        <p>
         As with sestamibi-based techniques, the sensitivity of ultrasound for parathyroid adenoma localization is reduced in patients with thyroid nodules [
         <a href="#rid73">
          73
         </a>
         ]. However, US is helpful for the characterization and evaluation of any thyroid pathology, facilitating operative planning. This is a common problem since concurrent thyroid pathology is present in 20 to 30 percent of patients with primary hyperparathyroidism [
         <a href="#rid74">
          74
         </a>
         ]. Concurrent thyroid disease should be addressed preoperatively (eg, with fine needle aspiration) and/or intraoperatively (eg, with concurrent thyroidectomy). In addition, US-directed fine needle aspiration biopsy with analysis of parathyroid hormone (PTH) levels can be helpful for confirming suspected parathyroid lesions such as intrathyroidal adenomas or cysts [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         Most experts in parathyroid surgery rely on both US and SPECT for preoperative localization, although this varies by geography and institutional expertise [
         <a href="#rid15">
          15,75,76
         </a>
         ]. Combining 99mTc-sestamibi scintigraphy with neck ultrasound provides high sensitivity (79 to 95 percent) for predicting the location of a single parathyroid adenoma [
         <a href="#rid63">
          63,64,77
         </a>
         ]. Sonography provides additional anatomic information about the thyroid gland that could alter surgical management [
         <a href="#rid78">
          78,79
         </a>
         ]. In a cost analysis study, initial ultrasound is the most cost-effective imaging modality, followed by 4D-CT [
         <a href="#rid80">
          80
         </a>
         ]. No imaging technique, even in combination, accurately predicts multiglandular disease, and a bilateral neck exploration should be strongly considered when the studies are discordant, equivocal, or negative [
         <a href="#rid52">
          52,81
         </a>
         ].
        </p>
        <p>
         Disadvantages to the use of US alone include decreased accuracy in patients with smaller parathyroid gland size, obesity, or mediastinal glands located behind the clavicles [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6958652">
         <span class="h2">
          Four-dimensional computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Four-dimensional computed tomography (4D-CT) scans take advantage of the rapid contrast uptake and washout that is characteristic of parathyroid adenomas for precise anatomic localization  (
         <a class="graphic graphic_diagnosticimage graphicRef82115" href="/z/d/graphic/82115.html" rel="external">
          image 4
         </a>
         ). The primary disadvantage of 4D-CT is the radiation exposure, which, compared with sestamibi imaging, results in a &gt;50-fold higher dose of radiation absorbed by the thyroid. The additional radiation leads to an age-dependent higher risk of developing thyroid cancer; hence, the use of 4D-CT should be highly selective in younger patients [
         <a href="#rid83">
          83
         </a>
         ]. Most protocols include noncontrast images followed by additional acquisitions (up to three) after contrast injection. However, protocols vary by center, and some utilize fewer acquisitions to limit the radiation exposure. In a meta-analysis inclusive of 34 published studies that evaluated CT imaging for parathyroid adenoma localization using a wide variety of protocols, each additional imaging acquisition resulted in a marginal increase in the pooled sensitivity for abnormal gland lateralization (sensitivity of single phase, 71 percent; two phase, 76 percent; three phase, 80 percent) [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         4D-CT is particularly useful in the reoperative setting when initial imaging with sestamibi is negative. In a study of 45 patients who had undergone previous neck exploration, 4D-CT had 88 percent sensitivity for abnormal parathyroid glands compared with sestamibi SPECT or neck US (54 and 21 percent, respectively) [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2891789">
         <span class="h2">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parathyroid adenoma characteristics on magnetic resonance imaging (MRI) include intermediate to low signal intensity on T1 imaging and high intensity on T2 imaging. Cervical lymph nodes can also have similar imaging characteristics, which limits the accuracy of MRI.
        </p>
        <p>
         For reoperative surgery, MRI may provide a useful noninvasive imaging modality to localize abnormal parathyroid tissue and does not require iodinated contrast or exposure to ionizing radiation [
         <a href="#rid86">
          86,87
         </a>
         ]. The reported sensitivity of MRI for abnormal parathyroid tissue ranges from 40 to 85 percent [
         <a href="#rid40">
          40,88,89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4090120">
         <span class="h2">
          Positron emission tomography and CT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of 11C-methionine positron emission tomography and computed tomography (MET-PET-CT) uses 11C-methionine as a radiotracer to identify pathologic parathyroid glands [
         <a href="#rid90">
          90-92
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study that included 102 patients undergoing a parathyroidectomy for primary hyperparathyroidism found that MET-PET-CT scan correctly located a single-gland adenoma in 83 of 97 patients (86 percent), with a positive predictive value of 93 percent [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a small single-institution series, MET-PET-CT has also been described as a useful option for patients who need reoperative surgery but have initial negative imaging [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In Europe and some selected centers, 18-fluorocholine-PET-CT has been used successfully and accurately to localize parathyroid adenomas. However, this technique is not widely adopted as the nuclear radiotracer is not commercially available and needs to be synthesized locally [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2019 systematic review, it had a sensitivity of 80 to 100 percent and a specificity of 95 to 100 percent [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a single US institution study of 58 patients undergoing initial parathyroid exploration with six-month cure, 18f-fluorocholine-PET findings were associated with the highest likelihood of cure (83 percent) compared with sestamibi (28 percent) or ultrasound (37 percent) [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis comparing 18-fluorocholine PET with 99mTc in identifying abnormal parathyroid glands in primary hyperparathyroidism demonstrated higher sensitivity for the former (97 percent, range 94 to 100) than the latter (55 percent, range 32 to 78) [
         <a href="#rid97">
          97
         </a>
         ]. The results were confounded by significant heterogeneity in imaging techniques for both nuclear radiotracers but particularly notable in the 99mTc studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2891782">
         <span class="h2">
          Invasive localization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Invasive procedures, such as selective venous sampling or selective arteriography, are reserved for patients who have had prior neck surgery and require reoperative surgery, in whom noninvasive testing has been unrevealing. Risks associated with invasive localization procedures include groin hematoma, anaphylaxis from the iodinated contrast, contrast-induced acute renal failure, and stroke. They are also expensive and require an experienced interventional radiologist to perform. Because of improvements in scanning and ultrasonography, as noted above, the need for invasive testing has declined substantially.
        </p>
        <p class="headingAnchor" id="H6958819">
         <span class="h3">
          Selective venous sampling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective venous sampling is the most common invasive modality used for parathyroid localization. A 1.5- to 2-fold increase in parathyroid hormone levels obtained from representative cervical vein drainage locations (inferior, middle, superior thyroid, thymic, and/or vertebral veins) compared with a peripheral location is considered an abnormal elevation. Selective venous sampling can identify hyperfunctioning parathyroid tissue when all other imaging modalities are negative [
         <a href="#rid71">
          71,98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6958878">
         <span class="h3">
          Selective arteriography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective arteriography is performed by combining selective transarterial hypocalcemic stimulation with nonselective venous sampling. Baseline and timed superior vena cava samplings are taken after injection with sodium citrate to induce hypocalcemia while simultaneous arteriography is performed. A positive localization is considered an increase in the parathyroid hormone level to 1.4 times the baseline or a blush seen on arteriography [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H709617">
         <span class="h1">
          NEGATIVE IMAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonlocalizing imaging studies should not preclude initial surgery for patients with biochemically confirmed primary hyperparathyroidism who meet operative criteria. In such patients, a single adenoma is still the most likely intraoperative finding (62 to 77 percent); however, multiglandular disease is more common than is typical in patients with primary hyperparathyroidism (20 to 38 percent) [
         <a href="#rid56">
          56,57
         </a>
         ]. These patients require bilateral exploration by an experienced parathyroid surgeon and the use of intraoperative parathyroid hormone monitoring [
         <a href="#rid51">
          51,99
         </a>
         ]. When compared to patients with localized studies, equivalent long-term biochemical cure rates can be achieved, although more extensive surgery may be needed [
         <a href="#rid56">
          56,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">
          "Parathyroid exploration for primary hyperparathyroidism"
         </a>
         .)
        </p>
        <p>
         It should also be mentioned that if initial imaging is negative at a medical facility that does not commonly perform parathyroid imaging, referral to a high-volume center should be considered. Sensitivity of localization has been reported to increase to as high as 92 percent in higher-volume centers [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3395063386">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114502.html" rel="external">
          "Society guideline links: Parathyroid surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of preoperative localization
         </strong>
         – Results of localization studies, interpreted in conjunction with intraoperative parathyroid hormone testing, can guide incision placement, minimize the extent of surgical dissection, and locate ectopic parathyroid tissue. The latter is particularly helpful in patients with recurrent or persistent hyperparathyroidism. (See
         <a class="local">
          'Minimally invasive and unilateral parathyroidectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Localization studies do not confirm the diagnosis of primary hyperparathyroidism when positive or rule out the diagnosis when negative. The diagnosis of primary hyperparathyroidism should be based upon biochemical evaluation. Localization studies do not reliably exclude multiglandular parathyroid disease and should not be used to select patients for surgery. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial parathyroidectomy
         </strong>
         – For initial minimally invasive surgery, the preferred localizing imaging studies include sestamibi scintigraphy (MIBI-SPECT imaging), ultrasound, and/or four-dimensional computed tomography (4D-CT). The type and number of studies ordered preoperatively are influenced by institutional and geographical expertise, as well as other clinical considerations. Additional complementary techniques are sometimes needed for patients with persistent/recurrent disease. (See
         <a class="local">
          'Imaging modalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reoperative parathyroidectomy
         </strong>
         – For all patients undergoing reoperation, we recommend performing preoperative localization (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest obtaining at least two imaging studies to assure concordance under these circumstances (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Reoperation for recurrent or persistent hyperparathyroidism'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kaplan EL, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. Ann Surg 1992; 215:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016; 151:959.
          </a>
         </li>
         <li class="breakAll">
          Rodgers SE, Carty SE. Primary Hyperparathyroidism. In: Fischer's Mastery of Surgery, 8th ed, Ellison EC, Upchurch GR (Eds), Wolters Kluwer, 2023. Vol 1, p.347.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res 2022; 37:2293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yip L, Pryma DA, Yim JH, et al. Can a lightbulb sestamibi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism? World J Surg 2008; 32:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrier N, Lang BH, Farias LCB, et al. Surgical Aspects of Primary Hyperparathyroidism. J Bone Miner Res 2022; 37:2373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arici C, Cheah WK, Ituarte PH, et al. Can localization studies be used to direct focused parathyroid operations? Surgery 2001; 129:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002; 235:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilezikian JP, Silverberg SJ, Bandeira F, et al. Management of Primary Hyperparathyroidism. J Bone Miner Res 2022; 37:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindié E, Mellière D, Perlemuter L, et al. Primary hyperparathyroidism: higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning. Radiology 1997; 204:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan JA Jr, Eisenberg B, Pado KM, Lee F. Efficacy of selective unilateral exploration in hyperparathyroidism based on localization tests. Arch Surg 1997; 132:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RC 2nd, Greenwell D, Flynn MB. Initial neck exploration for untreated hyperparathyroidism. Am Surg 2000; 66:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carneiro DM, Solorzano CC, Nader MC, et al. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 2003; 134:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riss P, Scheuba C, Asari R, et al. Is minimally invasive parathyroidectomy without QPTH monitoring justified? Langenbecks Arch Surg 2009; 394:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udelsman R, Åkerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donatini G, Marciniak C, Lenne X, et al. Risk Factors of Redo Surgery After Unilateral Focused Parathyroidectomy: Conclusions From a Comprehensive Nationwide Database of 13,247 Interventions Over 6 Years. Ann Surg 2020; 272:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallick R, Nicholson KJ, Yip L, et al. Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism. Surgery 2020; 167:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen W, Düren M, Morita E, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg 1996; 131:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery 1994; 116:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry JF. Reoperation for primary hyperparathyroidism: tips and tricks. Langenbecks Arch Surg 2010; 395:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caron NR, Sturgeon C, Clark OH. Persistent and recurrent hyperparathyroidism. Curr Treat Options Oncol 2004; 5:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996; 224:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udelsman R, Donovan PI. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg 2006; 244:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SG, Saunders ND, Jamshed S, et al. Multimodal Preoperative Localization Improves Outcomes in Reoperative Parathyroidectomy: A 25-Year Surgical Experience. Am Surg 2019; 85:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frey S, Couëtte C, Trésallet C, et al. Utility of a Second 99mTc-MIBI Scintigraphy Before Reoperation for Patients With Persistent Sporadic Primary Hyperparathyroidism: Results of a Retrospective Multicenter Study. Ann Surg Oncol 2020; 27:3831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cham S, Sepahdari AR, Hall KE, et al. Dynamic Parathyroid Computed Tomography (4DCT) Facilitates Reoperative Parathyroidectomy and Enables Cure of Missed Hyperplasia. Ann Surg Oncol 2015; 22:3537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacks BA, Pallotta JA, Cole A, Hurwitz J. Diagnosis of parathyroid adenomas: efficacy of measuring parathormone levels in needle aspirates of cervical masses. AJR Am J Roentgenol 1994; 163:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacFarlane MP, Fraker DL, Shawker TH, et al. Use of preoperative fine-needle aspiration in patients undergoing reoperation for primary hyperparathyroidism. Surgery 1994; 116:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism--an evidence-based analysis. Langenbecks Arch Surg 2009; 394:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin JJ, Milas M, Mitchell J, et al. Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery. Arch Surg 2011; 146:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hessman O, Stålberg P, Sundin A, et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg 2008; 32:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander HR Jr, Chen CC, Shawker T, et al. Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yen TW, Wang TS, Doffek KM, et al. Reoperative parathyroidectomy: an algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results in a successful focused approach. Surgery 2008; 144:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yip L, Ogilvie JB, Challinor SM, et al. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Surgery 2008; 144:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell BK, Kinder BK, Cornelius E, Stewart AF. Primary hyperparathyroidism: preoperative localization using technetium-sestamibi scanning. J Clin Endocrinol Metab 1995; 80:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Summers GW. Parathyroid exploration. A review of 125 cases. Arch Otolaryngol Head Neck Surg 1991; 117:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87:5353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosa JA, Powe NR, Levine MA, et al. Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab 1998; 83:2658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schell SR, Dudley NE. Clinical outcomes and fiscal consequences of bilateral neck exploration for primary idiopathic hyperparathyroidism without preoperative radionuclide imaging or minimally invasive techniques. Surgery 2003; 133:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udelsman R, Pasieka JL, Sturgeon C, et al. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. Radiographics 2008; 28:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am 2009; 89:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavely WC, Goetze S, Friedman KP, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 2007; 48:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prommegger R, Wimmer G, Profanter C, et al. Virtual neck exploration: a new method for localizing abnormal parathyroid glands. Ann Surg 2009; 250:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moure D, Larrañaga E, Domínguez-Gadea L, et al. 99MTc-sestamibi as sole technique in selection of primary hyperparathyroidism patients for unilateral neck exploration. Surgery 2008; 144:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindqvist V, Jacobsson H, Chandanos E, et al. Preoperative 99Tc(m)-sestamibi scintigraphy with SPECT localizes most pathologic parathyroid glands. Langenbecks Arch Surg 2009; 394:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilat H, Cohen M, Feinmesser R, et al. Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography. J Clin Ultrasound 2005; 33:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery 2006; 140:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med 2005; 35:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lal A, Chen H. The negative sestamibi scan: is a minimally invasive parathyroidectomy still possible? Ann Surg Oncol 2007; 14:2363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiu B, Sturgeon C, Angelos P. What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy. Surgery 2006; 140:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Civelek AC, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery 2002; 131:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler MH. Preoperative parathyroid scanning in secondary hyperparathyroidism. Lancet 1999; 353:2174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mihai R, Gleeson F, Buley ID, et al. Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients. World J Surg 2006; 30:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappu S, Donovan P, Cheng D, Udelsman R. Sestamibi scans are not all created equally. Arch Surg 2005; 140:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman K, Somervell H, Patel P, et al. Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery 2004; 136:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta NY, Ruda JM, Kapadia S, et al. Relationship of technetium Tc 99m sestamibi scans to histopathological features of hyperfunctioning parathyroid tissue. Arch Otolaryngol Head Neck Surg 2005; 131:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephen AE, Roth SI, Fardo DW, et al. Predictors of an accurate preoperative sestamibi scan for single-gland parathyroid adenomas. Arch Surg 2007; 142:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Ramírez J, Sancho-Insenser JJ, Pereira JA, et al. Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism. Langenbecks Arch Surg 2010; 395:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols KJ, Tomas MB, Tronco GG, et al. Preoperative parathyroid scintigraphic lesion localization: accuracy of various types of readings. Radiology 2008; 248:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wimmer G, Profanter C, Kovacs P, et al. CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism. Langenbecks Arch Surg 2010; 395:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachter PP, Issa N, Shimonov M, et al. Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy. Arch Surg 2004; 139:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spanu A, Falchi A, Manca A, et al. The usefulness of neck pinhole SPECT as a complementary tool to planar scintigraphy in primary and secondary hyperparathyroidism. J Nucl Med 2004; 45:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma J, Mazzaglia P, Milas M, et al. Radionuclide imaging for hyperparathyroidism (HPT): which is the best technetium-99m sestamibi modality? Surgery 2006; 140:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solorzano CC, Carneiro-Pla DM, Irvin GL 3rd. Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. J Am Coll Surg 2006; 202:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindié E, Mellière D, Jeanguillaume C, et al. Unilateral surgery for primary hyperparathyroidism on the basis of technetium Tc 99m sestamibi and iodine 123 subtraction scanning. Arch Surg 2000; 135:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber B, Moher C, Côté D, et al. Comparison of single photon emission CT (SPECT) with SPECT/CT imaging in preoperative localization of parathyroid adenomas: A cost-effectiveness analysis. Head Neck 2016; 38 Suppl 1:E2062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCoy KL, Ghodadra AG, Hiremath TG, et al. Sestamibi SPECT/CT versus SPECT only for preoperative localization in primary hyperparathyroidism: a single institution 8-year analysis. Surgery 2018; 163:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haber RS, Kim CK, Inabnet WB. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. Clin Endocrinol (Oxf) 2002; 57:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erbil Y, Barbaros U, Tükenmez M, et al. Impact of adenoma weight and ectopic location of parathyroid adenoma on localization study results. World J Surg 2008; 32:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell AC, Alexander HR, Chang R, et al. Reoperation for parathyroid adenoma: a contemporary experience. Surgery 2009; 146:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg 2008; 248:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaros U, Erbil Y, Salmashoğlu A, et al. The characteristics of concomitant thyroid nodules cause false-positive ultrasonography results in primary hyperparathyroidism. Am J Otolaryngol 2009; 30:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bentrem DJ, Angelos P, Talamonti MS, Nayar R. Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism? Thyroid 2002; 12:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elaraj DM, Sippel RS, Lindsay S, et al. Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results? Arch Surg 2010; 145:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Clinical review: Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 2013; 98:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel CN, Salahudeen HM, Lansdown M, Scarsbrook AF. Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin Radiol 2010; 65:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon JH, Kim EK, Lee HS, et al. Neck ultrasonography as preoperative localization of primary hyperparathyroidism with an additional role of detecting thyroid malignancy. Eur J Radiol 2013; 82:e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milas M, Mensah A, Alghoul M, et al. The impact of office neck ultrasonography on reducing unnecessary thyroid surgery in patients undergoing parathyroidectomy. Thyroid 2005; 15:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lubitz CC, Stephen AE, Hodin RA, Pandharipande P. Preoperative localization strategies for primary hyperparathyroidism: an economic analysis. Ann Surg Oncol 2012; 19:4202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haciyanli M, Lal G, Morita E, et al. Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg 2003; 197:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berber E, Parikh RT, Ballem N, et al. Factors contributing to negative parathyroid localization: an analysis of 1000 patients. Surgery 2008; 144:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahajan A, Starker LF, Ghita M, et al. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg 2012; 36:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluijfhout WP, Pasternak JD, Beninato T, et al. Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. Eur J Radiol 2017; 88:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortenson MM, Evans DB, Lee JE, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. J Am Coll Surg 2008; 206:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gotway MB, Reddy GP, Webb WR, et al. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology 2001; 218:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayender J, Lee TC, Ruan DT. Real-Time Localization of Parathyroid Adenoma during Parathyroidectomy. N Engl J Med 2015; 373:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakamatsu H, Noguchi S, Yamashita H, et al. Parathyroid scintigraphy with 99mTc-MIBI and 123I subtraction: a comparison with magnetic resonance imaging and ultrasonography. Nucl Med Commun 2003; 24:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez Hänninen E, Vogl TJ, Steinmüller T, et al. Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism. Invest Radiol 2000; 35:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang BN, Moreno-Reyes R, Blocklet D, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging 2008; 3:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrmann K, Takei T, Kanegae K, et al. Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol 2009; 11:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber T, Cammerer G, Schick C, et al. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res 2010; 42:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber T, Maier-Funk C, Ohlhauser D, et al. Accurate preoperative localization of parathyroid adenomas with C-11 methionine PET/CT. Ann Surg 2013; 257:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traub-Weidinger T, Mayerhoefer ME, Koperek O, et al. 11C-methionine PET/CT imaging of 99mTc-MIBI-SPECT/CT-negative patients with primary hyperparathyroidism and previous neck surgery. J Clin Endocrinol Metab 2014; 99:4199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boccalatte LA, Higuera F, Gómez NL, et al. Usefulness of 18F-Fluorocholine Positron Emission Tomography-Computed Tomography in Locating Lesions in Hyperparathyroidism: A Systematic Review. JAMA Otolaryngol Head Neck Surg 2019; 145:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graves CE, Hope TA, Kim J, et al. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery 2022; 171:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitman J, Allen IE, Bergsland EK, et al. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. J Nucl Med 2021; 62:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebastchi AH, Aruny JE, Donovan PI, et al. Real-Time Super Selective Venous Sampling in Remedial Parathyroid Surgery. J Am Coll Surg 2015; 220:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan RK, Ruan DT, Gawande AA, Moore FD Jr. Surgery for hyperparathyroidism in image-negative patients. Arch Surg 2008; 143:335.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2069 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1558410" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27532368" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27532368" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36245251" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18324345" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Can a lightbulb sestamibi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36054175" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Surgical Aspects of Primary Hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11391371" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Can localization studies be used to direct focused parathyroid operations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11981212" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Six hundred fifty-six consecutive explorations for primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36054638" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Management of Primary Hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9205251" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Primary hyperparathyroidism: higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9267274" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy of selective unilateral exploration in hyperparathyroidism based on localization tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759197" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Initial neck exploration for untreated hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14668730" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19440730" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Is minimally invasive parathyroidectomy without QPTH monitoring justified?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162669" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32833757" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk Factors of Redo Surgery After Unilateral Focused Parathyroidectomy: Conclusions From a Comprehensive Nationwide Database of 13,247 Interventions Over 6 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31606193" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712911" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Reoperation for persistent or recurrent primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7985102" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cost of unsuccessful surgery for primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19924438" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Reoperation for primary hyperparathyroidism: tips and tricks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15233910" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Persistent and recurrent hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8813259" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16926573" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Remedial parathyroid surgery: changing trends in 130 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31638503" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Multimodal Preoperative Localization Improves Outcomes in Reoperative Parathyroidectomy: A 25-Year Surgical Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32246313" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Utility of a Second 99mTc-MIBI Scintigraphy Before Reoperation for Patients With Persistent Sporadic Primary Hyperparathyroidism: Results of a Retrospective Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25691276" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dynamic Parathyroid Computed Tomography (4DCT) Facilitates Reoperative Parathyroidectomy and Enables Cure of Missed Hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7976905" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Diagnosis of parathyroid adenomas: efficacy of measuring parathormone levels in needle aspirates of cervical masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7985103" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Use of preoperative fine-needle aspiration in patients undergoing reoperation for primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19590890" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Imaging for primary hyperparathyroidism--an evidence-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22184303" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18335276" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High success rate of parathyroid reoperation may be achieved with improved localization diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12412790" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18847646" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Reoperative parathyroidectomy: an algorithm for imaging and monitoring of intraoperative parathyroid hormone levels that results in a successful focused approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19041010" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7829642" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Primary hyperparathyroidism: preoperative localization using technetium-sestamibi scanning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1747225" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Parathyroid exploration. A review of 125 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12466320" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709928" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12563235" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical outcomes and fiscal consequences of bilateral neck exploration for primary idiopathic hyperparathyroidism without preoperative radionuclide imaging or minimally invasive techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19193911" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794320" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19836493" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Surgical management of primary hyperparathyroidism: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17574983" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19806053" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Virtual neck exploration: a new method for localizing abnormal parathyroid glands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18707045" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 99MTc-sestamibi as sole technique in selection of primary hyperparathyroidism patients for unilateral neck exploration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19578871" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Preoperative 99Tc(m)-sestamibi scintigraphy with SPECT localizes most pathologic parathyroid glands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16134156" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17188140" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16150247" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Radionuclide imaging of the parathyroid glands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17522941" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The negative sestamibi scan: is a minimally invasive parathyroidectomy still possible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16934604" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854692" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10392976" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Preoperative parathyroid scanning in secondary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16680585" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15841562" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Sestamibi scans are not all created equally.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15657576" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967881" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Relationship of technetium Tc 99m sestamibi scans to histopathological features of hyperfunctioning parathyroid tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17441292" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Predictors of an accurate preoperative sestamibi scan for single-gland parathyroid adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20625763" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18483228" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Preoperative parathyroid scintigraphic lesion localization: accuracy of various types of readings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19705144" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15078713" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734671" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The usefulness of neck pinhole SPECT as a complementary tool to planar scintigraphy in primary and secondary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17188131" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Radionuclide imaging for hyperparathyroidism (HPT): which is the best technetium-99m sestamibi modality?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377493" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11115353" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Unilateral surgery for primary hyperparathyroidism on the basis of technetium Tc 99m sestamibi and iodine 123 subtraction scanning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26849426" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comparison of single photon emission CT (SPECT) with SPECT/CT imaging in preoperative localization of parathyroid adenomas: A cost-effectiveness analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29310821" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sestamibi SPECT/CT versus SPECT only for preoperative localization in primary hyperparathyroidism: a single institution 8-year analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12153604" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18210183" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Impact of adenoma weight and ectopic location of parathyroid adenoma on localization study results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19958942" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Reoperation for parathyroid adenoma: a contemporary experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18791362" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19563934" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The characteristics of concomitant thyroid nodules cause false-positive ultrasonography results in primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12593724" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20566979" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23345096" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Clinical review: Parathyroid localization and implications for clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338394" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22921682" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Neck ultrasonography as preoperative localization of primary hyperparathyroidism with an additional role of detecting thyroid malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16187914" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The impact of office neck ultrasonography on reducing unnecessary thyroid surgery in patients undergoing parathyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22825773" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Preoperative localization strategies for primary hyperparathyroidism: an economic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585407" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18571587" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Factors contributing to negative parathyroid localization: an analysis of 1000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22146947" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28189196" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18471717" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230657" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26132962" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Real-Time Localization of Parathyroid Adenoma during Parathyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12813193" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Parathyroid scintigraphy with 99mTc-MIBI and 123I subtraction: a comparison with magnetic resonance imaging and ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10901104" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18781582" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19340488" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20013649" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23478517" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Accurate preoperative localization of parathyroid adenomas with C-11 methionine PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25029418" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : 11C-methionine PET/CT imaging of 99mTc-MIBI-SPECT/CT-negative patients with primary hyperparathyroidism and previous neck surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31145436" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Usefulness of 18F-Fluorocholine Positron Emission Tomography-Computed Tomography in Locating Lesions in Hyperparathyroidism: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34301418" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33452040" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25868412" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Real-Time Super Selective Venous Sampling in Remedial Parathyroid Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18427019" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Surgery for hyperparathyroidism in image-negative patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
